ONPH Stock Overview
Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Oncology Pharma Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.0001 |
52 Week High | US$1.05 |
52 Week Low | US$0.000001 |
Beta | 0 |
1 Month Change | 9,900.00% |
3 Month Change | 9,900.00% |
1 Year Change | -99.94% |
3 Year Change | -100.00% |
5 Year Change | -100.00% |
Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
ONPH | US Biotechs | US Market | |
---|---|---|---|
7D | 9,900.0% | 0.9% | 0.4% |
1Y | -99.9% | 10.3% | 28.8% |
Return vs Industry: ONPH underperformed the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: ONPH underperformed the US Market which returned 29.5% over the past year.
Price Volatility
ONPH volatility | |
---|---|
ONPH Average Weekly Movement | 12,030.7% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ONPH's share price has been volatile over the past 3 months.
Volatility Over Time: ONPH's weekly volatility has decreased from 289540% to 12031% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | n/a | George Malesek | https://www.oncology-pharma.com |
Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019.
Oncology Pharma Inc. Fundamentals Summary
ONPH fundamental statistics | |
---|---|
Market cap | US$3.87k |
Earnings (TTM) | -US$15.27k |
Revenue (TTM) | US$10.21k |
0.0x
P/S Ratio0.0x
P/E RatioIs ONPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ONPH income statement (TTM) | |
---|---|
Revenue | US$10.21k |
Cost of Revenue | US$0 |
Gross Profit | US$10.21k |
Other Expenses | US$25.48k |
Earnings | -US$15.27k |
Last Reported Earnings
Mar 31, 2013
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did ONPH perform over the long term?
See historical performance and comparison